Device Companies Set Their Sights on Glaucoma

Drug therapy has dominated glaucoma management for decades, but novel device technologies are shifting the way this disease is managed, adding promising new options to the previously limited treatment continuum. For companies active in this field, along with an increasing number of VCs targeting ophthalmology, this shift marks the beginning of a tremendous new opportunity--one that will involve challenges and risks, but that also offers a huge payoff for those able to provide the right technology at the right time.